Multinational cost‐effectiveness analysis of empagliflozin for heart failure patients with ejection fraction >40%

AIMS: Heart failure is a chronic progressive condition, with considerable burden on patients' quality of life and economic burden for the healthcare systems. Before the approval of empagliflozin, there were no proven effective treatments for patients with heart failure with left ventricular eje...

Descripción completa

Detalles Bibliográficos
Autores principales: Kolovos, Spyros, Bellanca, Leana, Groyer, Harinala, Rosano, Giuseppe M.C., Solé, Alexandra, Gaultney, Jennifer, Linden, Stephan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10682900/
https://www.ncbi.nlm.nih.gov/pubmed/37670496
http://dx.doi.org/10.1002/ehf2.14470

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10682900/
https://www.ncbi.nlm.nih.gov/pubmed/37670496
http://dx.doi.org/10.1002/ehf2.14470

Ejemplares similares